147 related articles for article (PubMed ID: 11571564)
1. Development of formulations that enhance physical stability of viral vectors for gene therapy.
Croyle MA; Cheng X; Wilson JM
Gene Ther; 2001 Sep; 8(17):1281-90. PubMed ID: 11571564
[TBL] [Abstract][Full Text] [Related]
2. Factors that influence stability of recombinant adenoviral preparations for human gene therapy.
Croyle MA; Roessler BJ; Davidson BL; Hilfinger JM; Amidon GL
Pharm Dev Technol; 1998 Aug; 3(3):373-83. PubMed ID: 9742558
[TBL] [Abstract][Full Text] [Related]
3. Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo.
Croyle MA; Cheng X; Sandhu A; Wilson JM
Mol Ther; 2001 Jul; 4(1):22-8. PubMed ID: 11472102
[TBL] [Abstract][Full Text] [Related]
4. Stability of infectious recombinant adeno-associated viral vector in gene delivery.
Xu R; Rahimi M; Ma H; Fung P; Chang C; Xu S; During M
Med Sci Monit; 2005 Sep; 11(9):BR305-8. PubMed ID: 16127351
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy.
del Pozo-Rodríguez A; Solinís MA; Gascón AR; Pedraz JL
Eur J Pharm Biopharm; 2009 Feb; 71(2):181-9. PubMed ID: 18940256
[TBL] [Abstract][Full Text] [Related]
6. Screening of novel excipients for improving the stability of retroviral and adenoviral vectors.
Cruz PE; Silva AC; Roldão A; Carmo M; Carrondo MJ; Alves PM
Biotechnol Prog; 2006; 22(2):568-76. PubMed ID: 16599578
[TBL] [Abstract][Full Text] [Related]
7. Investigation on formulation and preparation of adenovirus encoding human endostatin lyophilized powders.
Chen S; Guo D; Guo B; Liu J; Shen Y; Xu X; Huang W; Guo S
Int J Pharm; 2012 May; 427(2):145-52. PubMed ID: 22234038
[TBL] [Abstract][Full Text] [Related]
8. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
Jooss K; Chirmule N
Gene Ther; 2003 Jun; 10(11):955-63. PubMed ID: 12756416
[TBL] [Abstract][Full Text] [Related]
9. Receptor targeting of adeno-associated virus vectors.
Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
[TBL] [Abstract][Full Text] [Related]
10. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
Wright JF; Qu G; Tang C; Sommer JM
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):174-8. PubMed ID: 12669452
[TBL] [Abstract][Full Text] [Related]
11. Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery.
Croyle MA; Anderson DJ; Roessler BJ; Amidon GL
Pharm Dev Technol; 1998 Aug; 3(3):365-72. PubMed ID: 9742557
[TBL] [Abstract][Full Text] [Related]
12. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
13. Localized viral vector delivery to enhance in situ regenerative gene therapy.
Hu WW; Wang Z; Hollister SJ; Krebsbach PH
Gene Ther; 2007 Jun; 14(11):891-901. PubMed ID: 17344901
[TBL] [Abstract][Full Text] [Related]
14. Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells.
Li L; Yang L; Scudiero DA; Miller SA; Yu ZX; Stukenberg PT; Shoemaker RH; Kotin RM
Gene Ther; 2007 May; 14(10):814-27. PubMed ID: 17330085
[TBL] [Abstract][Full Text] [Related]
15. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector.
Oehmig A; Cortés ML; Perry KF; Sena-Esteves M; Fraefel C; Breakefield XO
Gene Ther; 2007 Jul; 14(14):1078-91. PubMed ID: 17460718
[TBL] [Abstract][Full Text] [Related]
16. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice.
Petry H; Brooks A; Orme A; Wang P; Liu P; Xie J; Kretschmer P; Qian HS; Hermiston TW; Harkins RN
Gene Ther; 2008 Jan; 15(1):54-60. PubMed ID: 17960164
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer to the gastrointestinal tract after peroral administration of recombinant adeno-associated virus type 2 vectors.
Shao G; Greathouse K; Huang Q; Wang CM; Sferra TJ
J Pediatr Gastroenterol Nutr; 2006 Aug; 43(2):168-79. PubMed ID: 16877980
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
19. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation.
Wright JF; Le T; Prado J; Bahr-Davidson J; Smith PH; Zhen Z; Sommer JM; Pierce GF; Qu G
Mol Ther; 2005 Jul; 12(1):171-8. PubMed ID: 15963933
[TBL] [Abstract][Full Text] [Related]
20. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system.
Haskell RE; Hughes SM; Chiorini JA; Alisky JM; Davidson BL
Gene Ther; 2003 Jan; 10(1):34-42. PubMed ID: 12525835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
